what a surprise, page-19

intravenous relenza good news http://www.nature.com/news/2006/060814/full/060814-9.html


''At the moment, researchers may have a bit of time to develop new leads, since resistance to oseltamivir seems to be developing relatively slowly. And pharmacologists still have a few tricks up their sleeves. Other neuraminidase inhibitors are starting to enter clinical trials, including an intravenous versions of zanamivir and another promising drug called peramivir.

Zanamivir is already known to be effective — it's just that the inhaled version is impractical. "I'm very excited about an intravenous neuraminidase inhibitor," says Hayden. "It answers a real medical need because there is currently no injectable drug that can be given to very sick people."